Rossari Biotech Limited has announced its Q4 and FY26 earnings results, recording the highest quarterly and annual performance across key financial metrics. The company reported revenue from operations of Rs. 684.9 crore for Q4 FY26, representing an 18% year-on-year growth from Rs. 579.6 crore in Q4 FY25. EBITDA stood at Rs. 77.3 crore with a margin of 11.3%, while profit after tax reached Rs. 46.0 crore, marking a 34% increase compared to the same period last year.

Q4 FY26 Financial Highlights

The company achieved its highest quarterly revenue, EBITDA and PAT during the quarter. All business segments - HPPC, TSC and AHN - delivered healthy double-digit growth during the quarter, reflecting the strength of the diversified portfolio.

FY26 Annual Performance

For the full financial year ended March 31, 2026, Rossari Biotech recorded its highest annual revenue of Rs. 2,396.4 crore, growing 15% from Rs. 2,080.3 crore in FY25. Annual EBITDA increased to Rs. 286.0 crore with a margin of 11.9%, while PAT rose to Rs. 149.2 crore, up 9% from the previous year.

Management Commentary

Commenting on the performance, Mr. Edward Menezes, Promoter & Executive Chairman, and Mr. Sunil Chari, Promoter & Managing Director, stated that the company concluded the year on a strong note with Q4 FY26 marking the highest-ever quarterly revenue and EBITDA performance. They highlighted that the diversified portfolio and balanced presence across end-user industries helped navigate a mixed operating environment, including volatility from ongoing geopolitical conflicts.

The management noted that margins during the quarter were impacted by the prevailing raw material situation and lag in passing on cost inflation. They remain focused on calibrated pricing actions, improving product mix and driving operating leverage to support margin recovery over time.

Key Developments

Unitop commissioned the remaining 15,000 MTPA ethoxylation capacity at its Dahej facility on March 31, 2026, taking total installed ethoxylation capacity to 66,000 MTPA. The Board of Directors recommended a dividend of Re. 0.50 per share for FY 2025-26.

The company established a new Research and Development Facility at Koparkhairane, Navi Mumbai, and shifted its existing R&D facility from IIT Bombay. This transition marks a significant step-up in scale and ambition, positioning the company to drive faster innovation cycles and strengthen its competitive moat. Mr. Udeypaul Singh Gill was appointed as an Additional Director designated as Non-Executive, Independent Director of the company.

Regulatory Compliance

Pursuant to Regulation 30 and 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company published an extract of its consolidated audited financial results for the quarter and financial year ended March 31, 2026 in Financial Express (English) and Loksatta (Marathi) newspapers on April 28, 2026.

Rossari Biotech Limited has announced the completion of Ms. Aparna Sharma's tenure as Independent Director on April 28, 2026. The company informed stock exchanges about this corporate governance change under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Director Tenure Completion

Ms. Aparna Sharma (DIN: 07132341) completed her term as an Independent Director and consequently ceased to hold the position with effect from the end of day on April 28, 2026. The cessation was due to the natural completion of her current term as an Independent Director.

Board Committee Memberships

During her tenure, Ms. Aparna Sharma held significant positions across multiple board committees. She served as Chairperson of the Stakeholders Relationship Committee and was a member of three other key committees.

Ms. Aparna Sharma automatically ceased to be Chairperson and Member of all the aforementioned committees in Rossari Biotech Limited with effect from the end of day on April 28, 2026.

Management Acknowledgment

The Board of Directors and the Management of the Company placed on record their deep appreciation for the contributions made by Ms. Aparna Sharma during her association with the company over the years. The disclosure was made in compliance with SEBI Master Circular no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

The company secretary Parul Gupta signed the regulatory filing, ensuring proper compliance with listing obligations and disclosure requirements.